Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 34

1.

The HK2 Dependent "Warburg Effect" and Mitochondrial Oxidative Phosphorylation in Cancer: Targets for Effective Therapy with 3-Bromopyruvate.

Lis P, Dyląg M, Niedźwiecka K, Ko YH, Pedersen PL, Goffeau A, Ułaszewski S.

Molecules. 2016 Dec 15;21(12). pii: E1730. Review.

2.

Glutathione may have implications in the design of 3-bromopyruvate treatment protocols for both fungal and algal infections as well as multiple myeloma.

Niedźwiecka K, Dyląg M, Augustyniak D, Majkowska-Skrobek G, Cal-Bąkowska M, Ko YH, Pedersen PL, Goffeau A, Ułaszewski S.

Oncotarget. 2016 Oct 4;7(40):65614-65626. doi: 10.18632/oncotarget.11592.

3.

Screening the yeast genome for energetic metabolism pathways involved in a phenotypic response to the anti-cancer agent 3-bromopyruvate.

Lis P, Jurkiewicz P, Cal-Bąkowska M, Ko YH, Pedersen PL, Goffeau A, Ułaszewski S.

Oncotarget. 2016 Mar 1;7(9):10153-73. doi: 10.18632/oncotarget.7174.

4.

The complete genome of Blastobotrys (Arxula) adeninivorans LS3 - a yeast of biotechnological interest.

Kunze G, Gaillardin C, Czernicka M, Durrens P, Martin T, Böer E, Gabaldón T, Cruz JA, Talla E, Marck C, Goffeau A, Barbe V, Baret P, Baronian K, Beier S, Bleykasten C, Bode R, Casaregola S, Despons L, Fairhead C, Giersberg M, Gierski PP, Hähnel U, Hartmann A, Jankowska D, Jubin C, Jung P, Lafontaine I, Leh-Louis V, Lemaire M, Marcet-Houben M, Mascher M, Morel G, Richard GF, Riechen J, Sacerdot C, Sarkar A, Savel G, Schacherer J, Sherman DJ, Stein N, Straub ML, Thierry A, Trautwein-Schult A, Vacherie B, Westhof E, Worch S, Dujon B, Souciet JL, Wincker P, Scholz U, Neuvéglise C.

Biotechnol Biofuels. 2014 Apr 24;7:66. doi: 10.1186/1754-6834-7-66. eCollection 2014.

5.

Killing multiple myeloma cells with the small molecule 3-bromopyruvate: implications for therapy.

Majkowska-Skrobek G, Augustyniak D, Lis P, Bartkowiak A, Gonchar M, Ko YH, Pedersen PL, Goffeau A, Ułaszewski S.

Anticancer Drugs. 2014 Jul;25(6):673-82. doi: 10.1097/CAD.0000000000000094.

PMID:
24557015
6.

3-Bromopyruvate: a novel antifungal agent against the human pathogen Cryptococcus neoformans.

Dyląg M, Lis P, Niedźwiecka K, Ko YH, Pedersen PL, Goffeau A, Ułaszewski S.

Biochem Biophys Res Commun. 2013 May 3;434(2):322-7. doi: 10.1016/j.bbrc.2013.02.125. Epub 2013 Mar 26.

PMID:
23541578
7.

Yeast ATP-binding cassette transporters conferring multidrug resistance.

Prasad R, Goffeau A.

Annu Rev Microbiol. 2012;66:39-63. doi: 10.1146/annurev-micro-092611-150111. Epub 2012 Jun 11. Review.

PMID:
22703054
8.

Transport and cytotoxicity of the anticancer drug 3-bromopyruvate in the yeast Saccharomyces cerevisiae.

Lis P, Zarzycki M, Ko YH, Casal M, Pedersen PL, Goffeau A, Ułaszewski S.

J Bioenerg Biomembr. 2012 Feb;44(1):155-61. doi: 10.1007/s10863-012-9421-8. Epub 2012 Feb 23.

PMID:
22359102
9.

The mammalian ABC transporter ABCA1 induces lipid-dependent drug sensitivity in yeast.

Bocer T, Zarubica A, Roussel A, Flis K, Trombik T, Goffeau A, Ulaszewski S, Chimini G.

Biochim Biophys Acta. 2012 Mar;1821(3):373-80. doi: 10.1016/j.bbalip.2011.07.005. Epub 2011 Jul 20.

PMID:
21787882
10.

Evolution of the 12-spanner drug:H+ antiporter DHA1 family in hemiascomycetous yeasts.

Dias PJ, Seret ML, Goffeau A, Correia IS, Baret PV.

OMICS. 2010 Dec;14(6):701-10. doi: 10.1089/omi.2010.0104.

PMID:
21114408
11.

Vmr 1p is a novel vacuolar multidrug resistance ABC transporter in Saccharomyces cerevisiae.

Wawrzycka D, Sobczak I, Bartosz G, Bocer T, Ułaszewski S, Goffeau A.

FEMS Yeast Res. 2010 Nov;10(7):828-38. doi: 10.1111/j.1567-1364.2010.00673.x. Epub 2010 Sep 15.

12.

Fungal PDR transporters: Phylogeny, topology, motifs and function.

Lamping E, Baret PV, Holmes AR, Monk BC, Goffeau A, Cannon RD.

Fungal Genet Biol. 2010 Feb;47(2):127-42. doi: 10.1016/j.fgb.2009.10.007. Epub 2009 Oct 24. Review.

13.

Combined phylogeny and neighborhood analysis of the evolution of the ABC transporters conferring multiple drug resistance in hemiascomycete yeasts.

Seret ML, Diffels JF, Goffeau A, Baret PV.

BMC Genomics. 2009 Oct 1;10:459. doi: 10.1186/1471-2164-10-459.

14.

Efflux-mediated antifungal drug resistance.

Cannon RD, Lamping E, Holmes AR, Niimi K, Baret PV, Keniya MV, Tanabe K, Niimi M, Goffeau A, Monk BC.

Clin Microbiol Rev. 2009 Apr;22(2):291-321, Table of Contents. doi: 10.1128/CMR.00051-08. Review.

15.

Outwitting multidrug resistance to antifungals.

Monk BC, Goffeau A.

Science. 2008 Jul 18;321(5887):367-9. doi: 10.1126/science.1159746.

PMID:
18635793
16.

Drug resistance: the fight against fungi.

Goffeau A.

Nature. 2008 Apr 3;452(7187):541-2. doi: 10.1038/452541a. No abstract available.

PMID:
18385723
17.

Compensatory activation of the multidrug transporters Pdr5p, Snq2p, and Yor1p by Pdr1p in Saccharomyces cerevisiae.

Kolaczkowska A, Kolaczkowski M, Goffeau A, Moye-Rowley WS.

FEBS Lett. 2008 Mar 19;582(6):977-83. doi: 10.1016/j.febslet.2008.02.045. Epub 2008 Feb 26.

18.

A phylogenetic analysis of the sugar porters in hemiascomycetous yeasts.

Palma M, Goffeau A, Spencer-Martins I, Baret PV.

J Mol Microbiol Biotechnol. 2007;12(3-4):241-8.

PMID:
17587872
19.

Evolution of the carboxylate Jen transporters in fungi.

Lodi T, Diffels J, Goffeau A, Baret PV.

FEMS Yeast Res. 2007 Aug;7(5):646-56. Epub 2007 May 10.

20.

Genomics: multiple moulds.

Goffeau A.

Nature. 2005 Dec 22;438(7071):1092-3. No abstract available.

PMID:
16371993

Supplemental Content

Loading ...
Support Center